Close Menu Phone
Jane Sheridan

About Jane

Jane Sheridan practises in commercial and corporate law, with a particular focus on public company and insolvency matters. Involved in the privatisation of some of Australia’s largest publicly held assets, Jane has acted for equity investors in the acquisition of major infrastructure assets within the transport and electricity industries.

Her experience encompasses a wide range of corporate transactions, equity capital markets, M&A and regulatory compliance. Jane is recognised by Best Lawyers® International  in the area of corporate law and insolvency and reorganisation law and is recommended for corporate law, capital markets, restructuring and insolvency by the Legal 500 Asia Pacific. Jane has also recently been recommended by Doyle’s Guide in the category of ‘Leading Insolvency & Reconstruction Lawyers – Melbourne, 2016’.

In addition to her public company and insolvency work, Jane acts for a number of clients involved in the biotechnology sector, advising on commercialisation and other transactional matters. Jane was a member of the Takeovers Panel, a peer body which reviews corporate control transactions and resolves takeover disputes, from 2010 – 2016. She has been a commercial partner at Arnold Bloch Leibler since 1995.

Practice focus

Jane is a member of the commercial & corporate, insolvency, intellectual property and technology practices.  Her practice focuses on the following areas:
  • public listings and capital raisings, both on behalf of issuers and underwriters, including advice on Corporations Act regulatory requirements and Australian Stock Exchange (ASX) listing rule compliance;
  • infrastructure privatisation and major projects, including project documentation and structuring of equity participation;
  • corporate transactions and M&A, including sales and purchases of businesses, joint ventures, shareholders and subscription agreements, supply/distribution and other services agreements;
  • insolvency, including restructures and realisations involving complex corporate groups and managed investment schemes;
  • biotechnology, commercialisation and licensing, venture capital funds, research and development; and
  • corporate governance, licensing and regulatory compliance.


Snapshot of major assignments:

  • TPI Enterprises Limited, a licensed producer of narcotic raw materials: in relation to its capital raising and listing on ASX;
  • Hydration Pharmaceuticals Trust: in relation to its $85 million dollar sale of its Hydralyte business in Australia and New Zealand to Prestige Brands;
  • Fonterra: in relation to the sale of its Australian yoghurt and dairy desserts business to Parmalat Australia;
  • Tomizone Limited, a New Zealand integrated WiFi technology company: in relation to its reverse takeover of PHW Consolidated and backdoor listing on ASX;
  • Liquidators of Timbercorp: in relation to the effect of the Timbercorp group’s insolvency on the forestry and horticultural managed investment schemes operated by Timbercorp;
  • Liquidators of Gunns: in relation to the Gunns’ managed investment schemes including the sale of the timber plantations;
  • Liquidators of Willmott Forests: in relation to the collapse of Willmott Forests and its effect on the forestry managed investment schemes operated by Willmott Forests, including the sale of the timber plantations;
  • Premier Investments: in relation to its successful $900 million takeover of the Just Group;
  • The equity investors: in the $5.6 billion acquisition of Sydney Airport and the equity investors in each of the successful consortia in the acquisition of the Brisbane, Adelaide and Coolangatta Airports;
  • The equity investors and equity underwriters: to the successful consortia in relation to the $4.8 billion acquisition of the Loy Yang A power station and mine and in relation to the $2.4 billion acquisition of the Hazelwood power station and mine;
  • The equity underwriters: to the successful consortia in relation to the $4.9 billion Brisbane Airport Link, the $3.88 billion EastLink Project and the $1.8 billion CityLink Project; and
  • Acrux, a Melbourne-based biotechnology firm: in relation to its exclusive worldwide licensing agreement with US pharmaceutical giant, Eli Lilly, including US $335 million in milestones and worldwide royalties.

Recognition & publications

Take a look at Insights & News articles referencing Jane Sheridan.